Active Filter(s):
Details:
ZIPHIUS Therapeutics has prioritized its resources to intensify the development of ZIP-1642, a vaccine against the novel coronavirus.
Lead Product(s): ZIP-1642
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2020